BackContineum Therapeutics Overview
Contineum Therapeutics Inc. - Ordinary Shares - Class A

Contineum Therapeutics Target Price

Contineum Therapeutics target price — quarterly history, peer benchmarks, and growth trends.

Get informed when a big investor buys or sells

+ Follow

Share Price

$14.82

Average Target Price

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-14Morgan Stanley$168% upsideOpen
2026-01-08Morgan Stanley$145.5% downsideOpen
2025-11-24Robert W. Baird$145.5% downsideOpen
2025-11-21RBC CapitalBrian Abrahams$2248.4% upsideOpen
2025-09-25Leerink Partners$2035% upsideOpen
2025-03-07Robert W. Baird$168% upsideOpen
2024-10-21Robert W. BairdJoel Beatty$32115.9% upsideOpen
2024-04-30RBC CapitalBrian Abrahams$30102.4% upsideOpen
2024-04-30Stifel NicolausPaul Matteis$2995.7% upsideOpen

Contineum Therapeutics (CTNM) FAQ

Stockcircle tracks target price for Contineum Therapeutics (CTNM), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Target Price page is built for Contineum Therapeutics's historical target price trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use target price as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main CTNM overview so you can move from this figure to the surrounding analysis quickly.